Loading…
Therapeutic potential of CAR T cell in malignancies: A scoping review
Although tremendous advancements in cancer therapy over the last several years, cancer still is a complex illness to cure. Traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, have a poor therapeutic effect, emphasizing the significance of employing innovative treatments...
Saved in:
Published in: | Biomedicine & pharmacotherapy 2022-02, Vol.146, p.112512-112512, Article 112512 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3 |
---|---|
cites | cdi_FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3 |
container_end_page | 112512 |
container_issue | |
container_start_page | 112512 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 146 |
creator | Mehrabadi, Ali Zarezadeh Ranjbar, Reza Farzanehpour, Mahdieh Shahriary, Alireza Dorostkar, Ruhollah Hamidinejad, Mohammad Ali Ghaleh, Hadi Esmaeili Gouvarchin |
description | Although tremendous advancements in cancer therapy over the last several years, cancer still is a complex illness to cure. Traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, have a poor therapeutic effect, emphasizing the significance of employing innovative treatments like activated cell therapy. Chimeric antigen receptor T cell is one of the most prevalent types of activated cell therapy have been developed to direct T lymphocytes toward cancers (CAR-T cells). CAR-T cells therapy has illustrated poor impact versus solid tumors despite the remarkable success in patients suffering from hematological malignancies. CAR-T cells must overcome various hurdles to obtain full responses to solid tumors, including growth, stability, trafficking, and destiny inside tumors. As a result, novel treatment methods will entail overcoming the challenges that CAR-T cells face in solid tumors. The use of CAR-T cells in combination with other therapeutic approaches such as chemotherapy, radiotherapy, immuno-checkpoint inhibitors, and oncolytic viruses can promote the effectiveness of CAR-T cell therapy for the treatment of solid tumors. However, more research is needed to determine the safety and effectiveness of these therapies. CAR-T cell treatment success rates vary by type of disease, but are predicted to reach up to 90% in patients with leukemia. However, since this kind of immunotherapy is still in its infancy, there is much to learn about its efficacy. This review provided an in-depth examination of CAR-T cell therapy and its success and failure as a cancer treatment approach. We also discuss combination therapies with CAR-T Cell.
[Display omitted]
•CAR-T cell therapy is one of several treatments included in cancer immunotherapy.•CAR T cells have been categorized into fifth distinct generations.•CAR-T cell therapy is not entirely safe, and this strategy has notable limitations.•Combination therapies improve the function of CAR-T cell efficiency in solid tumors. |
doi_str_mv | 10.1016/j.biopha.2021.112512 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2609466729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332221012993</els_id><sourcerecordid>2609466729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3</originalsourceid><addsrcrecordid>eNp9kM1Lw0AQxRdRtFb_A5E9ekmd_UzWg1CKXyAIUs_LdjOtW9Ik7qaK_70pqR49zRzemzfvR8gFgwkDpq_Xk0Vo2nc34cDZhDGuGD8gI2YUZBogPyQjyJXIhOD8hJymtAYApUVxTE6ELIxUzIzI3fwdo2tx2wVP26bDuguuos2SzqavdE49VhUNNd24KqxqV_uA6YZOafJNG-oVjfgZ8OuMHC1dlfB8P8fk7f5uPnvMnl8enmbT58xLKLqsAPCMcwFY5Iwptyg0OlP0q3YAIvcyd1rysjSKe1RCeVkwEKXJjZcllmJMroa7bWw-tpg6uwlp96KrsdkmyzUYqXXOTS-Vg9THJqWIS9vGsHHx2zKwO4B2bQeAdgfQDgB72-U-YbvYYPln-iXWC24HAfY9--7Rpp5J7bEMEX1nyyb8n_ADKN-Arg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2609466729</pqid></control><display><type>article</type><title>Therapeutic potential of CAR T cell in malignancies: A scoping review</title><source>ScienceDirect Journals</source><creator>Mehrabadi, Ali Zarezadeh ; Ranjbar, Reza ; Farzanehpour, Mahdieh ; Shahriary, Alireza ; Dorostkar, Ruhollah ; Hamidinejad, Mohammad Ali ; Ghaleh, Hadi Esmaeili Gouvarchin</creator><creatorcontrib>Mehrabadi, Ali Zarezadeh ; Ranjbar, Reza ; Farzanehpour, Mahdieh ; Shahriary, Alireza ; Dorostkar, Ruhollah ; Hamidinejad, Mohammad Ali ; Ghaleh, Hadi Esmaeili Gouvarchin</creatorcontrib><description>Although tremendous advancements in cancer therapy over the last several years, cancer still is a complex illness to cure. Traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, have a poor therapeutic effect, emphasizing the significance of employing innovative treatments like activated cell therapy. Chimeric antigen receptor T cell is one of the most prevalent types of activated cell therapy have been developed to direct T lymphocytes toward cancers (CAR-T cells). CAR-T cells therapy has illustrated poor impact versus solid tumors despite the remarkable success in patients suffering from hematological malignancies. CAR-T cells must overcome various hurdles to obtain full responses to solid tumors, including growth, stability, trafficking, and destiny inside tumors. As a result, novel treatment methods will entail overcoming the challenges that CAR-T cells face in solid tumors. The use of CAR-T cells in combination with other therapeutic approaches such as chemotherapy, radiotherapy, immuno-checkpoint inhibitors, and oncolytic viruses can promote the effectiveness of CAR-T cell therapy for the treatment of solid tumors. However, more research is needed to determine the safety and effectiveness of these therapies. CAR-T cell treatment success rates vary by type of disease, but are predicted to reach up to 90% in patients with leukemia. However, since this kind of immunotherapy is still in its infancy, there is much to learn about its efficacy. This review provided an in-depth examination of CAR-T cell therapy and its success and failure as a cancer treatment approach. We also discuss combination therapies with CAR-T Cell.
[Display omitted]
•CAR-T cell therapy is one of several treatments included in cancer immunotherapy.•CAR T cells have been categorized into fifth distinct generations.•CAR-T cell therapy is not entirely safe, and this strategy has notable limitations.•Combination therapies improve the function of CAR-T cell efficiency in solid tumors.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2021.112512</identifier><identifier>PMID: 34894519</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antigenic Drift and Shift - immunology ; Chimeric antigen receptor T cells (CAR-T cells) ; Clinical trial ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Combinational therapies ; Combined Modality Therapy ; Hematologic Neoplasms - drug therapy ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapy, Adoptive - adverse effects ; Immunotherapy, Adoptive - methods ; Neoplasms - drug therapy ; Oncolytic Virotherapy - methods ; Oncolytic viruses ; Receptors, Chimeric Antigen - administration & dosage ; Receptors, Chimeric Antigen - therapeutic use ; Toxicities ; Tumor Microenvironment - immunology</subject><ispartof>Biomedicine & pharmacotherapy, 2022-02, Vol.146, p.112512-112512, Article 112512</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3</citedby><cites>FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34894519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mehrabadi, Ali Zarezadeh</creatorcontrib><creatorcontrib>Ranjbar, Reza</creatorcontrib><creatorcontrib>Farzanehpour, Mahdieh</creatorcontrib><creatorcontrib>Shahriary, Alireza</creatorcontrib><creatorcontrib>Dorostkar, Ruhollah</creatorcontrib><creatorcontrib>Hamidinejad, Mohammad Ali</creatorcontrib><creatorcontrib>Ghaleh, Hadi Esmaeili Gouvarchin</creatorcontrib><title>Therapeutic potential of CAR T cell in malignancies: A scoping review</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Although tremendous advancements in cancer therapy over the last several years, cancer still is a complex illness to cure. Traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, have a poor therapeutic effect, emphasizing the significance of employing innovative treatments like activated cell therapy. Chimeric antigen receptor T cell is one of the most prevalent types of activated cell therapy have been developed to direct T lymphocytes toward cancers (CAR-T cells). CAR-T cells therapy has illustrated poor impact versus solid tumors despite the remarkable success in patients suffering from hematological malignancies. CAR-T cells must overcome various hurdles to obtain full responses to solid tumors, including growth, stability, trafficking, and destiny inside tumors. As a result, novel treatment methods will entail overcoming the challenges that CAR-T cells face in solid tumors. The use of CAR-T cells in combination with other therapeutic approaches such as chemotherapy, radiotherapy, immuno-checkpoint inhibitors, and oncolytic viruses can promote the effectiveness of CAR-T cell therapy for the treatment of solid tumors. However, more research is needed to determine the safety and effectiveness of these therapies. CAR-T cell treatment success rates vary by type of disease, but are predicted to reach up to 90% in patients with leukemia. However, since this kind of immunotherapy is still in its infancy, there is much to learn about its efficacy. This review provided an in-depth examination of CAR-T cell therapy and its success and failure as a cancer treatment approach. We also discuss combination therapies with CAR-T Cell.
[Display omitted]
•CAR-T cell therapy is one of several treatments included in cancer immunotherapy.•CAR T cells have been categorized into fifth distinct generations.•CAR-T cell therapy is not entirely safe, and this strategy has notable limitations.•Combination therapies improve the function of CAR-T cell efficiency in solid tumors.</description><subject>Antigenic Drift and Shift - immunology</subject><subject>Chimeric antigen receptor T cells (CAR-T cells)</subject><subject>Clinical trial</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Combinational therapies</subject><subject>Combined Modality Therapy</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Neoplasms - drug therapy</subject><subject>Oncolytic Virotherapy - methods</subject><subject>Oncolytic viruses</subject><subject>Receptors, Chimeric Antigen - administration & dosage</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>Toxicities</subject><subject>Tumor Microenvironment - immunology</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kM1Lw0AQxRdRtFb_A5E9ekmd_UzWg1CKXyAIUs_LdjOtW9Ik7qaK_70pqR49zRzemzfvR8gFgwkDpq_Xk0Vo2nc34cDZhDGuGD8gI2YUZBogPyQjyJXIhOD8hJymtAYApUVxTE6ELIxUzIzI3fwdo2tx2wVP26bDuguuos2SzqavdE49VhUNNd24KqxqV_uA6YZOafJNG-oVjfgZ8OuMHC1dlfB8P8fk7f5uPnvMnl8enmbT58xLKLqsAPCMcwFY5Iwptyg0OlP0q3YAIvcyd1rysjSKe1RCeVkwEKXJjZcllmJMroa7bWw-tpg6uwlp96KrsdkmyzUYqXXOTS-Vg9THJqWIS9vGsHHx2zKwO4B2bQeAdgfQDgB72-U-YbvYYPln-iXWC24HAfY9--7Rpp5J7bEMEX1nyyb8n_ADKN-Arg</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Mehrabadi, Ali Zarezadeh</creator><creator>Ranjbar, Reza</creator><creator>Farzanehpour, Mahdieh</creator><creator>Shahriary, Alireza</creator><creator>Dorostkar, Ruhollah</creator><creator>Hamidinejad, Mohammad Ali</creator><creator>Ghaleh, Hadi Esmaeili Gouvarchin</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202202</creationdate><title>Therapeutic potential of CAR T cell in malignancies: A scoping review</title><author>Mehrabadi, Ali Zarezadeh ; Ranjbar, Reza ; Farzanehpour, Mahdieh ; Shahriary, Alireza ; Dorostkar, Ruhollah ; Hamidinejad, Mohammad Ali ; Ghaleh, Hadi Esmaeili Gouvarchin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigenic Drift and Shift - immunology</topic><topic>Chimeric antigen receptor T cells (CAR-T cells)</topic><topic>Clinical trial</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Combinational therapies</topic><topic>Combined Modality Therapy</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Neoplasms - drug therapy</topic><topic>Oncolytic Virotherapy - methods</topic><topic>Oncolytic viruses</topic><topic>Receptors, Chimeric Antigen - administration & dosage</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>Toxicities</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mehrabadi, Ali Zarezadeh</creatorcontrib><creatorcontrib>Ranjbar, Reza</creatorcontrib><creatorcontrib>Farzanehpour, Mahdieh</creatorcontrib><creatorcontrib>Shahriary, Alireza</creatorcontrib><creatorcontrib>Dorostkar, Ruhollah</creatorcontrib><creatorcontrib>Hamidinejad, Mohammad Ali</creatorcontrib><creatorcontrib>Ghaleh, Hadi Esmaeili Gouvarchin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mehrabadi, Ali Zarezadeh</au><au>Ranjbar, Reza</au><au>Farzanehpour, Mahdieh</au><au>Shahriary, Alireza</au><au>Dorostkar, Ruhollah</au><au>Hamidinejad, Mohammad Ali</au><au>Ghaleh, Hadi Esmaeili Gouvarchin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic potential of CAR T cell in malignancies: A scoping review</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2022-02</date><risdate>2022</risdate><volume>146</volume><spage>112512</spage><epage>112512</epage><pages>112512-112512</pages><artnum>112512</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Although tremendous advancements in cancer therapy over the last several years, cancer still is a complex illness to cure. Traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, have a poor therapeutic effect, emphasizing the significance of employing innovative treatments like activated cell therapy. Chimeric antigen receptor T cell is one of the most prevalent types of activated cell therapy have been developed to direct T lymphocytes toward cancers (CAR-T cells). CAR-T cells therapy has illustrated poor impact versus solid tumors despite the remarkable success in patients suffering from hematological malignancies. CAR-T cells must overcome various hurdles to obtain full responses to solid tumors, including growth, stability, trafficking, and destiny inside tumors. As a result, novel treatment methods will entail overcoming the challenges that CAR-T cells face in solid tumors. The use of CAR-T cells in combination with other therapeutic approaches such as chemotherapy, radiotherapy, immuno-checkpoint inhibitors, and oncolytic viruses can promote the effectiveness of CAR-T cell therapy for the treatment of solid tumors. However, more research is needed to determine the safety and effectiveness of these therapies. CAR-T cell treatment success rates vary by type of disease, but are predicted to reach up to 90% in patients with leukemia. However, since this kind of immunotherapy is still in its infancy, there is much to learn about its efficacy. This review provided an in-depth examination of CAR-T cell therapy and its success and failure as a cancer treatment approach. We also discuss combination therapies with CAR-T Cell.
[Display omitted]
•CAR-T cell therapy is one of several treatments included in cancer immunotherapy.•CAR T cells have been categorized into fifth distinct generations.•CAR-T cell therapy is not entirely safe, and this strategy has notable limitations.•Combination therapies improve the function of CAR-T cell efficiency in solid tumors.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34894519</pmid><doi>10.1016/j.biopha.2021.112512</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2022-02, Vol.146, p.112512-112512, Article 112512 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2609466729 |
source | ScienceDirect Journals |
subjects | Antigenic Drift and Shift - immunology Chimeric antigen receptor T cells (CAR-T cells) Clinical trial Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Combinational therapies Combined Modality Therapy Hematologic Neoplasms - drug therapy Humans Immune Checkpoint Inhibitors - therapeutic use Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Neoplasms - drug therapy Oncolytic Virotherapy - methods Oncolytic viruses Receptors, Chimeric Antigen - administration & dosage Receptors, Chimeric Antigen - therapeutic use Toxicities Tumor Microenvironment - immunology |
title | Therapeutic potential of CAR T cell in malignancies: A scoping review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A11%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20potential%20of%20CAR%20T%20cell%20in%20malignancies:%20A%20scoping%20review&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Mehrabadi,%20Ali%20Zarezadeh&rft.date=2022-02&rft.volume=146&rft.spage=112512&rft.epage=112512&rft.pages=112512-112512&rft.artnum=112512&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2021.112512&rft_dat=%3Cproquest_cross%3E2609466729%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-800c12230e87115ab86ea981156a0037c47a642dd952ce535c48103d979c4ded3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2609466729&rft_id=info:pmid/34894519&rfr_iscdi=true |